期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥希替尼致间质性肺病1例并文献复习

A case of interstitial lung disease caused by osimertinib mesylate and literature review
下载PDF
导出
摘要 报道1例65岁表皮生长因子受体19外显子缺失突变(E746_A750del)的右下肺腺癌患者,在服用奥希替尼100天后出现间质性肺病。停药后给予吸氧、糖皮质激素治疗后好转,尝试使用盐酸厄洛替尼片,未再发生间质性肺病。 This report presents a case of a 65-year-old patient with a right lower lobe adenocarcinoma of the lung,who had an exon 19 deletion mutation(E746_A750del)in the epidermal growth factor receptor(EGFR)gene and developed interstitial lung disease after taking osimertinib for 100 days.The patient improved after discontinuing osimertinib and receiving oxygen and glucocorticoid treatment.Then the patient tried erlotinib hydrochloride tablets,and interstitial lung disease did not occur again.
作者 李春梅 张英 赵海明 赵文瑞 代亚军 LI Chunmei;ZHANG Ying;ZHAO Haiming;ZHAO Wenrui;DAI Yajun(Department of Pharmacy,Xilin Gol League Central Hospital,Xilinhot,026000,Inner Mongolia,China;Department of Imaging,Xilin Gol League Central Hospital,Xilinhot,026000,Inner Mongolia,China;Department of Minimally Invasive Intervention,Xilin Gol League Central Hospital,Xilinhot,026000,Inner Mongolia,China)
机构地区 锡林郭勒盟中心医院药学部 锡林郭勒盟中心医院影像科 锡林郭勒盟中心医院微创介入科
出处 《肿瘤药学》 CAS 2024年第3期383-386,共4页 Anti-Tumor Pharmacy
关键词 奥希替尼 表皮生长因子受体酪氨酸激酶抑制剂 间质性肺病 肺腺癌 Osimertinib Epidermal growth factor receptors-tyrosine kinase inhibitors,EGFR-TKIs Interstitial lung disease Lung adenocarcinoma
分类号 R734.2 [医药卫生—肿瘤] R730.6 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献39

  • 1Gemma A. Drug-induced interstitial lung disease ( DILD) in mo-lecular targeted therapy[ J]. Int J Clin Oncol,2012,17(6) :533.
  • 2Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lungdisease in tyrosine kinase inhibitor therapy for non-small cell lungcancer: a review on current insight[ J]. Cancer Chemother Phar-macol, 2011,68(5):1099-1109.
  • 3Chou CL, Ko HW, Wang CW, et al. Erlotinib-associated Near-fatal Interstitial Pneumonitis in A Patient with Relapsed Lung Ad-enocarcinoma [J]. Chang Gung Med J,2010,33( 1) :100 -105.
  • 4Barber NA,Ganti AK. Pulmonary toxicities from targeted thera-pies: a review[ J]. Target Oncol, 2011,6(4) :235 -243.
  • 5Hotta K, Kiura K, Takigawa N, et al. Comparison of the inci-dence and pattern of interstitial lung disease during erlotinib andgefitinib treatment in Japanese patients with non-small cell lungcancer: the Okayama Lung Cancer Study Group experience[ J]. JThorac 0ncol,2010,5(2) : 179 -184.
  • 6Tian Q, Chen LA. Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitiallung disease[J]. Case Rep Oncol,2011,4(3) :464 -466.
  • 7Saito Y, Gemma A. Current status of DILD in molecular targetedtherapies[ J]. Int J Clin Oncol, 2012 ,17(6) :534 -541.
  • 8Ishiguro M, Watanabe T, Yamaguchi K, et al. A Japanese post-marketing surveillance of cetuximab( Erbitux? ) in patients withmetastatic colorectal cancerf J]. Jpn J Clin Oncol,2012,42(4):287 -294.
  • 9Matsuno 0. Drug-induced interstitial lung disease: mechanismsand best diagnostic approaches[ J] . Respir Res ,2012,13(1) :39.
  • 10Zhang Y, Yang H, Zhao M, et al. Successful treatment of ge-fitinib-induced acute interstitial pneumonitis with corticosteroidand non-invasive BIPAP-ventilation [ J ]. J Thorac Dis, 2012,4(3):316-319.

共引文献31

肿瘤药学
2024年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部